Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

April 09, 2019; 92 (15 Supplement) May 5, 2019

The Impact of Fremanezumab on Medication Overuse in Patients With Chronic Migraine (P1.10-026)

Stephen Silberstein, Sait Ashina, Zaza Katsarava, Kristen Bibeau, Michael Seminerio, Danielle Harlow, Joshua Cohen
First published April 16, 2019,
Stephen Silberstein
1Jefferson Headache Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA Philadelphia PA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sait Ashina
2Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA Brookline MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zaza Katsarava
3University of Essen, Unna, Germany Essen Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kristen Bibeau
4Teva Pharmaceuticals, Frazer, Pennsylvania, USA Frazer PA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Seminerio
4Teva Pharmaceuticals, Frazer, Pennsylvania, USA Frazer PA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Danielle Harlow
4Teva Pharmaceuticals, Frazer, Pennsylvania, USA Frazer PA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joshua Cohen
4Teva Pharmaceuticals, Frazer, Pennsylvania, USA Frazer PA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
The Impact of Fremanezumab on Medication Overuse in Patients With Chronic Migraine (P1.10-026)
Stephen Silberstein, Sait Ashina, Zaza Katsarava, Kristen Bibeau, Michael Seminerio, Danielle Harlow, Joshua Cohen
Neurology Apr 2019, 92 (15 Supplement) P1.10-026;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: To assess the effect of fremanezumab versus placebo on medication overuse and acute headache medication use in patients with chronic migraine (CM).

Background: Overuse of acute or symptomatic headache medications, such as triptans, ergot derivatives, opioids, and combination analgesics, can cause medication overuse headache (MOH). CM is often accompanied by MOH. Fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP), is efficacious in preventing CM.

Design/Methods: In this Phase 3, multicenter, randomized, double-blind, placebo-controlled study, CM patients were randomized 1:1:1 to receive subcutaneous fremanezumab quarterly (675 mg at baseline, and placebo at Weeks 4 and 8), fremanezumab monthly (675 mg at baseline, and 225 mg at Weeks 4 and 8), or placebo (at baseline, Weeks 4 and 8). We assessed the proportion of patients who reverted from overusing medications at baseline to not overusing medications during the 12-week treatment period, and the change from baseline in the number of days of acute headache medication use.

Results: Among patients with medication overuse at baseline (quarterly n=201; monthly n=198; placebo n=188), more patients treated with fremanezumab reported no medication overuse during the treatment period (quarterly: 55%, P=0.0389; monthly: 61%, P=0.0024) than those who received placebo (46%). Response to treatment was seen by Week 4 (quarterly: 51%, P=0.0091; monthly: 54%, P=0.0014; vs placebo: 39%). Among the patients who responded to treatment, the baseline number of days with medication overuse was similar across treatment groups (quarterly [mean]: 16.6 days; monthly: 16.7 days; placebo: 16.6). Within this population, fremanezumab treatment significantly reduced the days of acute headache medication use (quarterly: −9.0 days, P=0.0017; monthly: −8.9 days, P=0.0040) compared with those who received placebo (−7.1 days).

Conclusions: Fremanezumab treatment was associated with a reduction in overuse of acute medications and a corresponding decrease in days using acute medications.

Disclosure: Dr. Silberstein has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alder Biopharmaceuticals, Allergan, Amgen, Avanir, eNeura, ElectroCore Medical, Labrys Biologics, Medscape, Medtronic, Neuralieve, NINDS, Pfizer, and Teva. Dr. Silberstein has received compensation for serving on the Board of Directors of eNeura and Biohaven. Dr. Silberstein has received royalty, license fees, or contractual rights payments from Biohaven. Dr. Silberstein holds stock and/or stock options in Biohaven which sponsored research in which Dr. Silberstein was involved as an investigator. Dr. Silberstein holds stock and/or stock options in Biohaven. Dr. Silberstein has received research support from Allergan, Amgen, Cumberland Pharmaceuticals, ElectroCore Medical, Labrys Biologics, Eli Lilly, Merz, and Troy Healthcare.. Dr. Ashina has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Provides consultation to Allergan, Eli Lilly, Amgen, Novartis, and Promius and is a speaker for Teva Pharmaceuticals. Dr. Katsarava has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan, Novartis, Eli Lilly, and Teva Pharmaceuticals. Dr. Bibeau has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceuticals. Dr. Seminerio has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities as an employee of Teva Pharmaceuticals. Dr. Harlow has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with EMD Serono, Inc., Rockland, MA, USA (a business of Merck KGaA, Darmstadt, Germany). Dr. Cohen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of Teva Pharmaceuticals. Dr. Cohen has received research support from This study was funded by Teva Pharmaceuticals, Petach Tikva, Israel.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study

Dr. Robert Shapiro and Dr. Amynah Pradhan

► Watch

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 100 (4)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise